StockNews.com Begins Coverage on Zimmer Biomet (NYSE:ZBH)

StockNews.com began coverage on shares of Zimmer Biomet (NYSE:ZBH – Get Rating) in a report published on Thursday morning. The firm issued a buy rating on the medical equipment provider’s stock.

Several other research firms have also recently weighed in on ZBH. JMP Securities reissued a market outperform rating and issued a $145.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, February 7th. Robert W. Baird raised their target price on Zimmer Biomet from $133.00 to $145.00 in a research report on Monday, February 6th. Royal Bank of Canada raised Zimmer Biomet from a sector perform rating to an outperform rating and raised their target price for the stock from $125.00 to $141.00 in a research report on Monday, January 9th. Loop Capital raised their target price on Zimmer Biomet from $125.00 to $140.00 in a research report on Monday, February 6th. Finally, Morgan Stanley raised their target price on Zimmer Biomet from $135.00 to $140.00 and gave the stock an equal weight rating in a research report on Monday, February 6th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $133.56.

Zimmer Biomet Stock Down 0.9 %

ZBH opened at $124.31 on Thursday. Zimmer Biomet has a 1-year low of $100.39 and a 1-year high of $135.05. The company has a current ratio of 1.88, a quick ratio of 0.97 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $26.11 billion, a price-to-earnings ratio of 113.01, a P/E/G ratio of 2.87 and a beta of 1.00. The business has a 50 day moving average of $125.21 and a 200-day moving average of $118.70.

Zimmer Biomet (NYSE:ZBH – Get Rating) last posted its quarterly earnings data on Friday, February 3rd. The medical equipment provider reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.05. Zimmer Biomet had a return on equity of 11.97% and a net margin of 3.33%. The company had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.76 billion. During the same period in the prior year, the business earned $1.95 earnings per share. Zimmer Biomet’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zimmer Biomet will post 7.04 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Wednesday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. Zimmer Biomet’s payout ratio is presently 87.27%.

Institutional Trading of Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. Creative Capital Management Investments LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. New England Capital Financial Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $27,000. Clear Street Markets LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $27,000. Guardian Wealth Advisors LLC acquired a new stake in shares of Zimmer Biomet in the third quarter valued at $28,000. Finally, US Asset Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $33,000. 87.21% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.